Patents
Literature
Patsnap Copilot is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Patsnap Copilot

42 results about "Nucleoside monophosphate" patented technology

Structural elements of three nucleotides—where one-, two- or three-phosphates are attached to the nucleoside (in yellow, blue, green) at center: 1st, the nucleotide termed as a nucleoside monophosphate is formed by adding a phosphate group (in red); 2nd, adding a second phosphate group forms a nucleoside diphosphate; 3rd, adding a third phosphate ...

Plant nucleotide-sugar pyrophosphatase/phosphodiesterase (nppase), method of obtaining same and use of same in the production of assay devices and in the production of transgenic plants

Plant nucleotide pyrophosphatase / phosphodiesterase (NPPase), method of production, use in the manufacture of testing devices and in the production of transgenic plants. NPPase is an enzyme that catalyses the hydrolysis of a wide range of small molecules with phosphodiester and phosphosulphate bonds, in particular ADPG (adenosine diphosphate glucose) and APS (adenosine 5′-phosphosulphate). The enzyme obtained from plant extracts is used in assay devices for determining levels of nucleoside diphosphate sugars, based either on the sugar-1-phosphate released, or on the nucleoside monophosphate, both of which are products formed by the reaction catalysed by NPPase, as well as the detection of sulphonucleotides such as 3′-phosphoadenosine 5′-phosphosulphate (PAPS) and APS. The amino acid sequence of the enzyme is also described, as well as the nucleotide sequence of a complete cDNA and another incomplete cDNA. Finally, it describes the production of transgenic plants that overexpress NPPase and that have a high content of sugars, low content of starch and cell-wall polysaccharides and high resistance to high concentrations of salts and high temperature.
Owner:UNIV PUBLICA DE NAVARRA PAMPLONA +1

Pharmaceutical formulation containing remdesivir and its active metabolites for dry powder inhalation

InactiveUS20210353650A1Decrease and remove viral loadEffective and easy to administerPowder deliveryOrganic active ingredientsDiseaseRespiratory disease
The invention provides a pharmaceutical composition for dry powder inhalation and a preparation method thereof, wherein the composition comprises, a carrier material, preferably lactose and micronized remdesivir and / or its active metabolites (such as Alanine metabolite (Ala-met), Nucleoside monophosphate, and Nucleoside Triphosphate (NTP)) and / or its analog GS-441524 and pharmaceutically acceptable salts thereof. The active pharmaceutical ingredient may be an anti-viral, taken as remdesivir and / or its active metabolites (such as Alanine metabolite (Ala-met), Nucleoside monophosphate. and Nucleoside Triphosphate (NTP)) and / or its analog GS-441524. The dry powder inhalation containing Remdesivir and / or its active metabolites and / or its analog GS-441524 as active ingredients, further consisting of a breath-powered, dry powder inhaler, and a cartridge for delivering a dry powder formulation deep into the lungs for the treatment of respiratory disorders. The inhaler and cartridge can be provided with a drug delivery formulation comprising, for example, an active ingredient, including, small organic molecules, including, remdesivir and / or its active metabolites (such as Alanine metabolite (Ala-met), Nucleoside monophosphate, and Nucleoside Triphosphate (NTP)) and / or its analog GS-441524 and pharmaceutically acceptable salts thereof for the treatment of disease and disorders, for example, COVID-19 and other viral respiratory infections.
Owner:ANOVENT PHARM U S LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products